Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2410408 | Vaccine | 2006 | 11 Pages |
Abstract
We describe a study testing fibrillar β-amyloid1–42 (Aβ42) vaccination in dogs. Three young beagles (4.6 years) were immunized twice with Aβ42 and a Th1 adjuvant (TiterMax Gold). Animals generated primarily IgG2 and IgM antibody responses, which were specific for the Aβ11–30 region of Aβ1–42. Next, 3 aged beagles (8.9–13.8 years) were immunized 4 times with Aβ42 and a Th2 adjuvant (Alum). We observed an acute increase in IgG2, a slower increase in IgG1 and Aβ antibodies of broader specificity (Aβ1–15> Aβ11–30> Aβ6–20). A nonsignificant increase in CSF Aβ1–40 and decrease in Aβ1–40/1–42 in cortex was detected. Canines may be a useful system for testing an Aβ vaccine.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Elizabeth Head, Edward G. Barrett, M. Paul Murphy, Pritam Das, Mihaela Nistor, Floyd Sarsoza, Charles C. Glabe, Rakez Kayed, Saskia Milton, Vitaly Vasilevko, Norton W. Milgram, Michael G. Agadjanyan, David H. Cribbs, Carl W. Cotman,